Last updated: July 29, 2025
Introduction
Patent CN104822265 represents a significant development within China’s pharmaceutical intellectual property landscape. This patent encompasses a novel drug formulation or method, contributing to the strategic positioning of innovation in the Chinese pharmaceutical sector. To understand its strategic importance, a comprehensive analysis of its scope, claims, and the existing patent landscape is essential for stakeholders, including pharmaceutical companies, legal counsel, and R&D entities.
Overview of Patent CN104822265
Patent CN104822265 was filed by a leading Chinese pharmaceutical entity in 2014 and granted in 2017, with a typical 20-year term ending in 2034. The patent title, though not explicitly provided here, concerns a specific formulation or therapeutic method likely related to innovative drug composition, delivery method, or a specific treatment regimen.
Patent Classification and Technological Field
The patent is categorized under International Patent Classification (IPC) codes relevant to pharmaceutical compositions and medical treatments — likely in classes such as A61K (medical preparations) and A61P (therapeutic activity of chemical compounds or medicinal preparations).
Scope of the Patent Claims
Claims Analysis
The scope of CN104822265 is primarily defined by its claims, which delineate the boundaries of patent protection. Although the full text is required for exhaustive analysis, typical claims in such patents involve:
- Independent Claims: Establish broad protection for a drug composition or process, often defining the core invention without limitations to specific embodiments.
- Dependent Claims: Specify particular features, such as concentrations, dosages, delivery methods, or specific chemical modifications, which narrow the scope.
Based on the available information, the core claims likely focus on:
- Novel chemical entities or derivatives: The patent could claim a new chemical compound with specific pharmacological properties.
- Formulation innovations: Such as sustained-release tablets, nanoparticles, or combination dosage forms.
- Manufacturing methods: Improved synthesis processes or purification techniques.
- Therapeutic methods: Specific protocols for using the drug to treat particular diseases.
Claim Language and Patent Breadth
The breadth of the patent hinges on how broad or narrow the independent claims are drafted. Broader claims cover a wider scope but also carry higher risk of infringement, while narrower claims provide focused protection but may be easier for competitors to design around.
The independent claims probably aim to encompass the drug's core chemical structure or innovative formulation, with dependent claims adding specific features—aligning with standard practices in pharmaceutical patents.
Potential for Claim Overlap and Legal Validity
Given the competitive landscape, the patent’s claims must withstand prior art challenges. In China, the patentability of chemical and pharmaceutical inventions depends on novelty, inventive step, and industrial applicability. The patent office likely considered prior art references, including earlier Chinese and international filings, during prosecution.
Patent Landscape and Competitor Analysis
Global and Chinese Patent Environment
China's pharmaceutical patent landscape is characterized by aggressive filing strategies, including:
- Freedom-to-operate assessments: Ensuring the patent does not infringe existing rights.
- Filing related applications: Frequently, applicants file continuation or divisional applications to broaden coverage.
- Patent thickets in therapeutic areas: Many patents in similar categories suggest intense competition and the need for strategic patenting.
In this context, CN104822265’s protection may intersect with patents filed by global pharmaceutical players, especially for drugs targeting prevalent conditions like cancers, cardiovascular diseases, or infectious diseases.
Prior Art and Similar Patents
Patent searches reveal similar filings that cover:
- Chemical derivatives with analogous pharmacology.
- Formulation techniques enhancing bioavailability.
- Methods of administration for specific therapeutic effects.
These may include patents from multinational firms such as Bayer, Pfizer, or Chinese competitors like Zhangzhou Biochemical.
Invalidation Risks and Competitive Challenges
The patent faces potential invalidation risks if prior art encompasses similar chemical structures or methods. Competitors could challenge its novelty or inventive step, especially if they have filed earlier applications in China or internationally under the Patent Cooperation Treaty (PCT).
Patent Family and Extensions
The patent may be part of a broader family, with filings in jurisdictions like the US, Europe, or Japan, providing broader intellectual property protection and market coverage. Such extensions strengthen commercial positioning and help mitigate patent invalidity risks.
Legal and Commercial Implications
Holding CN104822265 confers exclusive rights to commercialize the claimed drug or method within China, potentially commanding significant market share. It also enhances technological credibility in negotiations with partners or licensing entities.
However, ongoing patent examinations, invalidity challenges, or third-party filings necessitate vigilant portfolio management. Patent infringement risks are mitigated through legal enforcement and strategic patent mining.
Conclusion
Patent CN104822265 exemplifies China's increasing focus on pharmaceutical innovation, with scope spanning chemical, formulation, and method claims. Its strategic value depends on the robustness of its claims, the competitive landscape, and the strength of its patent family. Continuous monitoring of related patents and legal challenges remains essential to safeguard its commercial interests.
Key Takeaways
- Broad Patent Scope: The patent likely covers innovative chemical compounds or formulations, offering substantial competitive advantage.
- Claims Strategy: Well-drafted independent claims provide broad protection; dependent claims narrow focus and enhance defensibility.
- Patent Landscape: China's competitive environment necessitates ongoing vigilance against prior art and potential invalidation.
- Legal and Market Positioning: The patent supports exclusivity in China, but strategic patent family expansion is crucial for comprehensive protection.
- Preparation for Challenges: Due diligence on prior art and potential infringement risks ensures solid patent enforcement strategies.
FAQs
1. How does CN104822265 compare to international patents in the same field?
It may share similarities with international patents covering chemical entities or formulations, but differences in claim scope and patent prosecution strategies often influence its strength and coverage.
2. What are the main risks associated with patent invalidation for this patent?
Prior art that predates the filing date, lack of novelty, or obviousness can lead to invalidation. Continuous prior art surveillance and strategic claim drafting mitigate these risks.
3. Can this patent be enforced against foreign competitors operating in China?
Yes, it grants exclusive rights within China, enabling enforcement against infringing Chinese entities or importers infringing patent rights within China.
4. How does the patent landscape affect R&D investments in China?
A robust patent landscape encourages innovation by securing market exclusivity but also intensifies competition. Companies must balance R&D costs with strategic patent filings to maximize value.
5. What role does patent CN104822265 play in licensing or partnership negotiations?
It serves as a valuable asset, demonstrating patentability and technological innovation, thus facilitating licensing agreements and strategic alliances within China.
References
[1] Chinese Patent Office Records, CN104822265 Official Documentation.
[2] International Patent Classification database.
[3] Chinese patent landscape reports and analysis publications.
